Log In
Print
BCIQ
Print
Print this Print this
 

Elaprase, idursulfase (SHP609) (formerly HGT2310)

Also known as: iduronate-2-sulfatase (formerly I2S)

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionIduronate-2-sulfatase enzyme
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis II (MPS II, Hunter syndrome); Treat mucopolysaccharidosis II (MPS II, Hunter syndrome) in patients with CNS symptoms; Treat neurocognitive decline associated with mucopolysaccharidosis II (MPS II, Hunter syndrome)
Regulatory Designation

U.S. - Fast Track (Treat neurocognitive decline associated with mucopolysaccharidosis II (MPS II, Hunter syndrome));
U.S. - Fast Track (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome) in patients with CNS symptoms);
U.S. - Orphan Drug (Treat mucopolysaccharidosis II (MPS II, Hunter syndrome) in patients with CNS symptoms)

Partner

Endo International plc; Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today